非T细胞去除单倍体移植与同胞全合或无关供者移植在继发性急性髓系白血病首次完全缓解中的比较:ALWP/EBMT研究
该注册研究分析了2010-2022年间3862例首次完全缓解的继发性急性髓系白血病患者,比较单倍体、同胞全合和无关供者移植。多变量分析显示同胞全合移植总生存优于单倍体移植(HR 0.76),单倍体与无关供者移植结局相当,无同胞全合供者时两者均为可行选择。
要点
- 同胞全合移植较单倍体移植复发风险高但非复发死亡和急性GVHD风险低,总生存更优。
- 无关供者移植非复发死亡低于单倍体移植,但总生存和GVHD风险无显著差异。
- 供者类型不影响无白血病生存和GVHD无复发生存。
核心结论
- 在继发性急性髓系白血病首次完全缓解患者中,同胞全合移植提供最佳结局。
- 单倍体移植与无关供者移植结局相当,无同胞全合供者时两者均为可行替代。
研究设计与样本
- 回顾性注册研究,纳入2010-2022年间3862例首次完全缓解的继发性急性髓系白血病患者接受异基因造血干细胞移植。
- 供者类型:单倍体643例,同胞全合715例,无关供者2504例;中位随访3.3年。
主要发现
- 同胞全合移植较单倍体移植复发风险高(HR 1.64),但非复发死亡(HR 0.32)和II-IV级急性GVHD风险(HR 0.54)低,总生存更优(HR 0.76)。
- 无关供者移植较单倍体移植非复发死亡低(HR 0.63),但总生存和GVHD风险无显著差异。
- 供者类型对无白血病生存和GVHD无复发生存无显著影响。
- 不良细胞遗传学和减低强度预处理与复发风险增加相关;较低Karnofsky评分、较大年龄和不良细胞遗传学独立预测更差的非复发死亡、无白血病生存、总生存和GRFS。
- 女性供者至男性受者增加慢性GVHD风险。
临床怎么用
- 继发性急性髓系白血病首次完全缓解患者优先选择同胞全合供者。
- 无同胞全合供者时,单倍体移植和无关供者移植均可作为替代方案。
局限性
- 回顾性注册研究,组间在患者和供者年龄、预处理方案、干细胞来源和GVHD预防方面存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HSCT in patients with sAML in first complete remission (CR1). Data from 3862 patients (Haplo = 643, MSD = 715, MUD = 2504) transplanted between 2010 and 2022 were analyzed, with a median follow-up of 3.3 years. Groups differed in patient and donor age, conditioning regimen, stem cell source, and graft-versus-host disease (GVHD) prophylaxis. Multivariate analysis showed that MSD-HSCT had a higher relapse risk than Haplo-HSCT (hazard ratio [HR]: 1.64) but lower non-relapse mortality (NRM, HR: 0.32) and acute GVHD risk (HR: 0.54 for grade II-IV), leading to an overall survival (OS) benefit (HR: 0.76). MUD-HSCT had lower NRM than Haplo-HSCT (HR: 0.63) but there were no significant differences in OS or GVHD risk. Donor type did not impact leukemia-free survival (LFS) or GVHD-free and relapse-free survival (GRFS). Adverse cytogenetics and reduced-intensity conditioning were associated with increased relapse risk, while lower Karnofsky scores, older age, and adverse cytogenetics independently predicted worse NRM, LFS, OS, and GRFS outcomes. Female-to-male donor-recipient pairs had an increased risk of chronic GVHD. In this registry-based analysis, MSD offered the best outcomes for sAML in CR1. Haplo-HSCT was comparable to MUD-HSCT, despite a higher NRM, and achieved long-term disease control in 60% of patients due to a low relapse incidence. In the absence of an MSD, both Haplo and MUD are viable alternatives.
引用
- Nagler A, Kayser S, Ferhat AT, et al. Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT. Am J Hematol. 2025. PMID: 41351865. doi:10.1002/ajh.70164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。